BRPI0915517A2 - sacarídeos vi conjugados - Google Patents

sacarídeos vi conjugados

Info

Publication number
BRPI0915517A2
BRPI0915517A2 BRPI0915517A BRPI0915517A BRPI0915517A2 BR PI0915517 A2 BRPI0915517 A2 BR PI0915517A2 BR PI0915517 A BRPI0915517 A BR PI0915517A BR PI0915517 A BRPI0915517 A BR PI0915517A BR PI0915517 A2 BRPI0915517 A2 BR PI0915517A2
Authority
BR
Brazil
Prior art keywords
saccharides
conjugates
Prior art date
Application number
BRPI0915517A
Other languages
English (en)
Inventor
Micoli Francesca
Berti Francesco
Costantino Paolo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0915517A2 publication Critical patent/BRPI0915517A2/pt
Publication of BRPI0915517B1 publication Critical patent/BRPI0915517B1/pt
Publication of BRPI0915517B8 publication Critical patent/BRPI0915517B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
BRPI0915517A 2008-06-13 2009-06-12 método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica BRPI0915517B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0810894.6 2008-06-13
GBGB0810894.6A GB0810894D0 (en) 2008-06-13 2008-06-13 Conjugated saccharide
PCT/IB2009/006285 WO2009150543A2 (en) 2008-06-13 2009-06-12 Conjugated vi saccharides

Publications (3)

Publication Number Publication Date
BRPI0915517A2 true BRPI0915517A2 (pt) 2017-06-20
BRPI0915517B1 BRPI0915517B1 (pt) 2020-10-06
BRPI0915517B8 BRPI0915517B8 (pt) 2021-05-25

Family

ID=39672273

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915517A BRPI0915517B8 (pt) 2008-06-13 2009-06-12 método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica

Country Status (18)

Country Link
US (2) US20110142876A1 (pt)
EP (1) EP2303333B1 (pt)
CN (1) CN102089009B (pt)
AU (1) AU2009259017B2 (pt)
BR (1) BRPI0915517B8 (pt)
CA (1) CA2727565C (pt)
CY (1) CY1116379T1 (pt)
DK (1) DK2303333T3 (pt)
ES (1) ES2537019T3 (pt)
GB (1) GB0810894D0 (pt)
HR (1) HRP20150527T1 (pt)
HU (1) HUE025512T2 (pt)
NZ (1) NZ590089A (pt)
PL (1) PL2303333T3 (pt)
PT (1) PT2303333E (pt)
SI (1) SI2303333T1 (pt)
WO (1) WO2009150543A2 (pt)
ZA (1) ZA201009304B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102120761B (zh) * 2010-12-24 2013-02-06 新疆维吾尔自治区畜牧科学院兽医研究所 一种无荚膜型金黄色葡萄球菌胞外多糖-蛋白质偶联物的制备方法
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
KR102447303B1 (ko) * 2013-08-24 2022-09-23 브하라트 바이오테크 인터내셔날 리미티드 박테리아성 백신 및 그의 제조방법
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US20190134177A1 (en) * 2016-04-25 2019-05-09 National Institute Of Immunology Conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate
BR112019003992A2 (pt) 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5738855A (en) 1994-10-17 1998-04-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide
US7527797B1 (en) 2000-09-01 2009-05-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae 0139 conjugate vaccines
WO2003094961A1 (en) * 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
JP5814507B2 (ja) * 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
EP2303333A2 (en) 2011-04-06
BRPI0915517B1 (pt) 2020-10-06
WO2009150543A2 (en) 2009-12-17
GB0810894D0 (en) 2008-07-23
US20130142822A1 (en) 2013-06-06
SI2303333T1 (sl) 2015-06-30
HUE025512T2 (hu) 2016-05-30
HRP20150527T1 (xx) 2015-06-19
AU2009259017B2 (en) 2014-12-11
ZA201009304B (en) 2012-08-29
US9475846B2 (en) 2016-10-25
BRPI0915517B8 (pt) 2021-05-25
US20110142876A1 (en) 2011-06-16
WO2009150543A3 (en) 2010-05-06
DK2303333T3 (da) 2015-05-26
CA2727565A1 (en) 2009-12-17
PL2303333T3 (pl) 2015-11-30
CA2727565C (en) 2017-01-10
PT2303333E (pt) 2015-06-08
CN102089009A (zh) 2011-06-08
NZ590089A (en) 2012-12-21
CN102089009B (zh) 2013-12-04
AU2009259017A1 (en) 2009-12-17
CY1116379T1 (el) 2017-02-08
EP2303333B1 (en) 2015-02-18
ES2537019T3 (es) 2015-06-01

Similar Documents

Publication Publication Date Title
PT2813570T (pt) Resumo
FIC20240018I1 (fi) Vamoroloni
DE602009000234D1 (de) msignals
BRPI0907376A2 (pt) Fotobiorretador
PT3045471T (pt) Resumo
UA18712S (uk) Шоколад
EP2329802A4 (en) EMBEDDED AUDIOPHONE
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2336132T3 (da) Morpholinpurinderivat
DK2335031T3 (da) In-line-måler
EP2206502A4 (en) POLYMER CONJUGATE OF A STEROIDS
SI2340271T1 (sl) Konjugati polimer-bioaktivnega sredstva
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI0907522A2 (pt) biarlamidas
DE112009000183A5 (de) Sicherheitsvorreiber
DK2278899T3 (da) Bryggemekanisme
BRPI0909634A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse
DE112009001946A5 (de) Mobelauszugsführung
DE602009000488D1 (de) Obstvereinzelvorrichtung
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
BRPI0909637A2 (pt) 2-aminoquinolinas
BRPI0915517A2 (pt) sacarídeos vi conjugados

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), A61P 43/00 (2006.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. (BE)